Fifty 1 Labs, Inc. Celebrates
Groundbreaking SpaceX, NASA, and ISS Yeast Experiment by Subsidiary
Genetic Networks
Groundbreaking Yeast Experiment from
Dr. Nislow's lab on Last Night's SpaceX Fram2 Mission Advances
Space-Based Biotechnology
Melbourne, FL -- April 1, 2025 -- InvestorsHub
NewsWire -- Fifty 1 Labs, Inc. (Ticker:
FITY), a forward-thinking leader in biotechnology and health
innovation, proudly announces a significant milestone in space
research achieved by its recently acquired subsidiary, Genetic
Networks. This milestone stems from over a decade of space-based
functional genomics from Dr. Corey Nislow's laboratory. Beginning
with STS-135, the final Space Shuttle mission to the ISS, through a
successful sample return following lunar orbit on Artemis I,
reported by CBC News on January 18, 2023 (https://www.cbc.ca/news/canada/british-columbia/yeast-space-experiment-1.6711816),
this work highlights the pivotal role of functional genomics in
diverse aspects of human health and wellness.
"These
experiments are crucial to build a solid foundation to understand
how life can adapt to the stresses of space, including microgravity
and cosmic radiation beyond our planet," Dr. Nislow stated, as
quoted in the original CBC report. "The data we've gathered could
unlock new pathways for pharmaceutical development and human health
in space exploration." His leadership and innovative approach have
solidified Genetic Networks' reputation as a pioneer in genetic
profiling, a strength that now significantly enhances Fifty 1 Labs'
capabilities following the acquisition.
Since integrating
Genetic Networks into its portfolio, Fifty 1 Labs has gained not
only cutting-edge technology but also the invaluable contributions
of Dr. Nislow, whose work bridges terrestrial biotechnology with
space exploration. His vision for leveraging genetic insights to
solve complex biological challenges aligns seamlessly with Fifty 1
Labs' mission to advance human health. The yeast experiment's
findings—made possible through Dr. Nislow's expertise—open doors to
applications ranging from resilient biological systems for
long-duration space missions to novel therapeutics for Earth-based
medicine.
Looking ahead,
Genetic Networks is expanding its collaboration with SpaceX, with
multiple missions planned for 2025 and the years to come.
"We are thrilled to
celebrate this achievement by Genetic Networks and to have Dr.
Corey Nislow as a key part of our team through this acquisition,"
said Gennaro D'Urso, CEO of Fifty 1 Labs, Inc. "Corey's leadership
in space genomics, combined with Genetic Networks' upcoming SpaceX
missions, exemplifies the forward-thinking innovation we aim to
champion at Fifty 1 Labs. His presence brings tremendous value,
amplifying our ability to push the boundaries of biotechnology on
Earth and beyond."
In the Nislow labs' latest experiment which launched last night on
SpaceX's Fram2 mission, yeast strains were engineered to express
transgenes derived from tardigrades, micro animals that are known
for their extraordinary resistance to radiation, were flown to
measure their response to microgravity and cosmic radiation.
The data will inform terrestrial applications for these
transgenes in humans, including those undergoing radiation-based
cancer therapies.
Fifty 1 Labs, Inc.
invites investors, researchers, and the public to follow its
journey as it leverages this milestone to drive innovation.
Investor Relations
877-814-4188
ir@fifty1labs.com
Website: https://geneticnetworks.com/
About Fifty 1 Labs, Inc. (FITY)
Fifty 1 Labs, Inc.
(Ticker: FITY) is a dynamic biotechnology company dedicated to
advancing human health through innovative research and development.
With a focus on cutting-edge solutions, Fifty 1 Labs integrates
advanced scientific discoveries to address challenges in medicine,
wellness, and beyond.
About Genetic Networks
Genetic Networks, a
wholly owned subsidiary of Fifty 1 Labs, Inc., specializes in
genetic profiling and bioinformatics, delivering transformative
insights into biological systems. Led by experts like Dr. Corey
Nislow, its contributions to space-based research and terrestrial
applications position it as a key player in the future of
biotechnology.
Safe Harbor Statement:
The information provided in this release may contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Identifiable by words
such as "may," "will," "should," "plans," "expects," "anticipates,"
"continue," "estimate," "project," "intend," and similar
expressions, these statements may also be made in written or oral
form in the company's filings with the U.S. Securities and Exchange
Commission, OTC Markets, press releases, other written materials,
or in oral statements made by its officers, directors, or employees
to third parties. There can be no assurance that such statements
will prove to be accurate. The company cautions that these
forward-looking statements are further qualified by other factors
including, but not limited to, those set forth in the company's
Disclosure Statements. Forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially
from those projected or anticipated. These risks and uncertainties
include, but are not limited to, general economic and business
conditions, effects of continued geopolitical unrest and regional
conflicts, competition, changes in technology and methods of
marketing, delays in completing various engineering and
manufacturing programs, changes in customer order patterns, changes
in product mix, continued success in technological advances and
delivering technological innovations, shortages in components,
production delays due to performance quality issues with outsourced
components, and various other factors beyond the company's control.
The company does not undertake any obligation to update publicly or
to revise any statements in this release, whether as a result of
new information, future events, or otherwise.
